June 30, 2026 05:30 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India overtakes Taiwan, South Korea to become world's fifth-largest equity market again | Pakistan strikes terror hideouts near Afghan border after Karachi bloodshed, 29 killed | Israel strikes back: Top October 7 militant “eliminated” in precision operation | Radharaman Das, who defended Bengal's vegetarian mid-day meal plan, loses ISKCON post | Fresh paper leak rocks India: Maharashtra TET postponed a day before exam, over 4 lakh aspirants affected | Pune fort murder case: Siya Goyal's brother says family would have called off marriage if she had objected | Donald Trump gets a road named after him in India, says 'Thank You!' | Fresh setback for Gautam Adani? US judge asks DoJ to justify dropping criminal charges | Ram Mandir Trust chief Champat Rai resigns as alleged donation siphoning row escalates | Ram Mandir fund row deepens: 8 arrested days after BJP called allegations 'false narrative'

Lupin launches generic Aricept tablets in the US

| | Mar 31, 2016, at 09:23 pm
Mumbai/ Baltimore, Mar 31 (IBNS) Mumbai-based Lupin Limited (Lupin), a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally, announced on Thursday that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept® Tablets, 23mg.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. works in the area of generic medicines and branded formulations.
 
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept® Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type.
 
Aricept® had US sales of USD 47.1 million (IMS MAT December 2015).

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm